Sinopharm-led consortium offers to take HK-listed China-TCM private in $3b deal

Sinopharm-led consortium offers to take HK-listed China-TCM private in $3b deal

FILE PHOTO: The logo of Sinopharm, China's National Pharmaceutical Group Corporation is pictured in Beijing, China January 18, 2022. REUTERS/Fabrizio Bensch/File Photo

A consortium led by state-owned pharma giant Sinopharm has revived a take-private bid for China Traditional Chinese Medicine Holdings, the Hong Kong-listed drugmaker said on Wednesday, valuing it at HK$23.16 billion ($2.96 billion).

China National Pharmaceutical, also known as Sinopharm, had in 2021 decided against a possible privatisation of China TCM.

Sinopharm, the parent of China-TCM, already holds a 32.46% stake in China-TCM and has offered to pay HK$4.6 per share in cash to buyout the drugmaker.

The offer price represents a 34.11% premium to the traditional medicine maker’s closing price of HK$3.43 per share before trading in the stock was halted.

The deal, if goes through, would be one of the biggest privatisation deal for a Hong-Kong listed firm since Haier Electronics’ $5 billion acquisition in 2020.

Sinopharm has also indicated it will not raise the offer price to take China-TCM private.

The offer comes as the drugmaker lags a surge in valuations for many mainland-listed Chinese medicinal firms in and around the COVID-19 pandemic.

“Whether the privatisation would be successful this time still depends on the outcome of negotiations among different parties, which is full of uncertainty,” said Xinyao (Criss) Wang, HK/China healthcare analyst at Smartkarma in a note.

The potential deal would add to a surge in strategic investors and buyout firms tapping Hong Kong for take-private opportunities. Buyers often cite undervalued shares as a reason for the deals.

Media reports had earlier emerged in 2022 over Sinopharm and its advisers preparing a potential offer of about HK$6 for each China-TCM share.

China TCM shares had jumped as much as 10% to HK$3.43 on Wednesday, taking its market value to HK$16.9 billion.

The drugmaker had in late January said it expects its 2023 net income to likely increase by 85% to 95%.

Reuters

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

This is your last free story for the month. Register to continue reading our content